A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia Journal Articles

Overview
Research
Identity
Additional Document Info
View All

abstract

Key Points Intermediate-dose cytarabine can be safely combined with TDZ at 50 mg every 6 hours in older patients with relapsed or refractory AML. A 5-day monotherapy with TDZ led to reduced blast counts in 5 out of 11 patients and was associated with patient-specific DRD2 level.

authors

Aslostovar, Lili
Boyd, Allison L
Almakadi, Mohammed
Collins, Tony J
Leong, Darryl
Tirona, Rommel G
Kim, Richard B
Julian, James
Xenocostas, Anargyros
Leber, Brian
Levine, Mark Norman
Foley, Ronan
Bhatia, Mick

status

published

publication date

August 14, 2018

has subject area

Aged (MeSH)
Antineoplastic Combined Chemotherapy Protocols (MeSH)
Cytarabine (MeSH)
Dopamine D2 Receptor Antagonists (MeSH)
Female (MeSH)
Humans (MeSH)
Hydroxyurea (MeSH)
Leukemia, Myeloid, Acute (MeSH)
Male (MeSH)
Middle Aged (MeSH)
Thioridazine (MeSH)

published in

Blood Advances Journal